Anti-HERV-K Drugs and Vaccines, Possible Therapies against Tumors

Area of Science:

• Oncology
• Virology
• Genetics

Background:

• Human endogenous retroviruses (HERV), especially HERV-K, are implicated in numerous cancers, including melanoma and breast cancer.
• HERV-K's biological activity stems from complete open reading frames (ORF) for Gag, Pol, and Env genes, enhancing infectivity and viral obstruction.
• Tumorigenesis may involve HERV-K products like Gag, Env, and reverse transcriptase (RT), alongside LINE-1 elements, through overexpression or methylation.

Purpose of the Study:

• To review the association between HERV-K and tumorigenicity.
• To present evidence linking HERV-K to cancer development.
• To introduce current and potential therapies for HERV-K-associated tumors.

Main Methods:

• Literature review of studies on HERV-K and cancer.
• Analysis of evidence linking HERV-K gene products to tumor formation.
• Compilation of information on therapeutic strategies targeting HERV-K.

Main Results:

• HERV-K's presence and activity are documented across diverse malignancies.
• Overexpression/methylation of HERV-K components (Gag, Env, RT) and LINE-1 are observed in tumors.
• Current therapies focus on suppressing HERV-K products or managing autoimmune responses.

Conclusions:

• HERV-K plays a significant role in tumorigenesis, though its exact role as an initiator or promoter requires further investigation.
• Understanding HERV-K's involvement is crucial for developing targeted therapies.
• Further research is needed to elucidate the precise mechanisms of HERV-K in cancer and refine therapeutic approaches.